Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma.

Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, Moore MA.

Blood. 2004 Jan 1;103(1):258-66. Epub 2003 Sep 11.

2.

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.

Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.

Cancer Res. 2003 Oct 1;63(19):6187-94.

3.

Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.

Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL.

Hepatology. 2005 Nov;42(5):1127-36.

PMID:
16114043
4.

A novel telomerase template antagonist (GRN163) as a potential anticancer agent.

Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin AC, Harley CB, Gryaznov S.

Cancer Res. 2003 Jul 15;63(14):3931-9.

5.

Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.

Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM.

Oncogene. 2005 Aug 4;24(33):5262-8.

PMID:
15940257
6.

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.

Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC.

Clin Cancer Res. 2004 Jan 15;10(2):770-6.

7.

Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.

Herbert BS, Pongracz K, Shay JW, Gryaznov SM.

Oncogene. 2002 Jan 21;21(4):638-42. Erratum in: Oncogene 2002 Apr;21(17):2774. Shea-Herbert Brittney [corrected to Herbert Brittney-Shea].

8.

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC.

Mol Cancer Ther. 2003 Sep;2(9):825-33.

9.

Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.

Brachner A, Sasgary S, Pirker C, Rodgarkia C, Mikula M, Mikulits W, Bergmeister H, Setinek U, Wieser M, Chin SF, Caldas C, Micksche M, Cerni C, Berger W.

Cancer Res. 2006 Apr 1;66(7):3584-92.

10.

Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents.

Gryaznov S, Asai A, Oshima Y, Yamamoto Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin A, Harley C, Akinaga S, Yamashita Y.

Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):577-81.

PMID:
14565232
11.

Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.

Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL.

Cancer Res. 2003 Feb 1;63(3):579-85.

12.

Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, Lamborn KR, Deen DF.

Neuro Oncol. 2004 Jul;6(3):218-26.

13.

Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor.

Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC.

Gastroenterology. 2004 May;126(5):1337-46.

PMID:
15131795
14.

Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth.

Cassar L, Li H, Pinto AR, Nicholls C, Bayne S, Liu JP.

Cancer Res. 2008 Nov 15;68(22):9157-66. doi: 10.1158/0008-5472.CAN-08-1323.

16.
17.

Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.

El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM.

Blood. 2005 Feb 15;105(4):1742-9. Epub 2004 Oct 26.

18.

Telomerase activity in vivo in human malignant hematopoietic cells.

Nilsson P, Mehle C, Remes K, Roos G.

Oncogene. 1994 Oct;9(10):3043-8.

PMID:
8084612
19.

[Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].

Chen XJ, Zheng W, Chen LL, Chen ZB, Wang SQ.

Zhonghua Yi Xue Za Zhi. 2004 Oct 17;84(20):1721-5. Chinese.

PMID:
15569435
20.

CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G.

Cancer Res. 2002 Jun 1;62(11):3106-12.

Supplemental Content

Support Center